Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
Key Highlights
- ➤PREPARE trial met its primary endpoint in hard-to-heal diabetic foot ulcers
- ➤PuraPly AM plus standard care significantly improved 12-week wound closure
- ➤Peer-reviewed results published in the Journal of Wound Care
- ➤Organogenesis expects evidence to support future PuraPly AM coverage decisions
Expert Statements
Patrick Bilbo, Chief Operating Officer of Organogenesis
“The PREPARE study adds to our large and growing body of data for PuraPly AM, including real-world evidence from registry and comparative effectiveness studies, and health economics and outcomes research.”
Patrick Bilbo, Chief Operating Officer of Organogenesis
“We expect this evidence to form the basis for future coverage decisions for PuraPly AM.”
Patrick Bilbo, Chief Operating Officer of Organogenesis
“Peer-reviewed data continues to differentiate us in a recalibrated market where Organogenesis is gaining share while competitors without comparable evidence are pivoting away from wound care or exiting the market altogether.”
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE(1), a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly(®)AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly(®)AM plus SoC, providing clinical evidence supporting the use of PuraPly(®)AM in one of the most costly and difficult-to-treat chronic wound populations.
"The PREPARE study adds to our large and growing body of data for PuraPly AM, including real-world evidence from registry and comparative effectiveness studies, and health economics and outcomes research," said Patrick Bilbo, Chief Operating Officer of Organogenesis. "We expect this evidence to form the basis for future coverage decisions for PuraPly AM. Peer-reviewed data continues to differentiate us in a recalibrated market where Organogenesis is gaining share while competitors without comparable evidence are pivoting away from wound care or exiting the market altogether."
Get started
Create a free account to read the full story.